高危皮肤黑色素瘤术后随访:影像联合查体与单纯查体的TRIM试验中期分析
TRIM是一项瑞典多中心随机3期试验,评估IIB-C和III期皮肤黑色素瘤根治术后随访中全身影像(CT或FDG-PET-CT)联合查体是否优于单纯查体。
要点
- 高危黑色素瘤术后随访加入全身影像未显示总生存获益。
- 远处转移无生存的数值差异促使研究按方案继续至最终分析。
核心结论
- 中期分析提示高危皮肤黑色素瘤术后随访中加入影像检查未带来生存获益。
- 仅少数参与者完成5年随访,远处转移无生存的数值差异支持按方案继续研究。
研究设计与样本
- TRIM为瑞典多中心随机3期 trial,纳入18岁以上、根治术后IIB-C或III期皮肤黑色素瘤患者。
- 参与者1:1随机分为单纯查体组(标准组)或查体联合全身影像组(实验组),按肿瘤分期和影像评估方法分层。
- 实验组在基线、6、12、24和36个月接受CT或[18F]FDG-PET-CT,目标样本量1300例。
- 中期分析纳入983例,标准组498例(男性296例,女性202例),实验组485例(男性309例,女性176例)。
- 主要终点为5年总生存,将在最终分析报告;中期报告未预设终点,按意向干预分析。
临床怎么用
- 对于IIB-C和III期皮肤黑色素瘤根治术后患者,中期结果不支持常规在随访中加入全身影像以改善生存。
- 临床决策应等待最终分析结果,目前可继续按指南进行查体为主的随访。
局限性
- 仅为中期分析,仅少数参与者完成5年随访,主要终点数据尚不成熟。
- 中期报告未预设终点,结果需最终分析验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In several countries, whole-body imaging has been introduced in the routine follow-up of individuals with high-risk cutaneous malignant melanoma after surgery. However, there is scarce evidence that earlier detection of recurrent disease by regular scanning improves survival. In this interim analysis, we investigated whether imaging in the follow-up programme for high-risk cutaneous malignant melanoma improves survival and assessed whether the study should continue to include participants. METHODS: TRIM is a multicentre, randomised, phase 3 trial in Sweden. Eligible participants are aged 18 years and older with sufficient renal function for intravenously contrast-enhanced CT and are expected to be fit for treatment in case of recurrence. After radical surgery of stage IIB-C and III cutaneous malignant melanoma, participants were randomly assigned (1:1, stratified by tumour stage and method of radiological assessment) to 3 years of follow-up by physical examinations alone (standard group) or to physical examinations plus whole-body imaging with CT or [18F]fluorodeoxyglucose-PET-CT at baseline, 6, 12, 24, and 36 months (experimental group). The goal is to include 1300 participants. The primary endpoint is overall survival at 5 years and will be reported in the final analysis when data are mature. In this interim report, no endpoints were predefined; we present overall survival, relapse-free survival, locoregional relapse-free survival, and distant metastasis-free survival, analysed by intention to intervene. This study is registered with ClinicalTrials.gov, NCT03116412, and recruitment is ongoing. FINDINGS: Between June 8, 2017, and July 28, 2023, 983 participants were randomly allocated to the standard (n=498; 296 [59%] male, 202 [41%] female) or experimental (n=485; 309 [64%] male, 176 [36%] female) group. There were no statistically significant differences in overall survival (not reached [NR; 95% CI NR-NR] vs NR [NR-NR]; hazard ratio [HR] 1·04 [95% CI 0·71-1·51], p=0·85) or distant metastasis-free survival (NR [NR-NR] vs NR [NR-NR]; HR 1·20 [0·89-1·64], p=0·24) between the groups at a median follow-up time of 33·6 months (IQR 16·3-49·8). 3-year overall survival rates were 88·2% (95% CI 85·0-91·6) in the standard group versus 87·7% (84·3-91·3) in the experimental group and distant metastasis-free survival was 81·6% (77·9-85·6) in the standard group versus 79·3% (75·3-83·5) in the control group. INTERPRETATION: This interim analysis indicated that there is no benefit from imaging in the follow-up programme for individuals with high-risk cutaneous malignant melanoma. However, only a few participants have completed the follow-up time of 5 years, and the numerical difference between the study groups in distant metastasis-free survival motivates us to continue the study according to protocol. FUNDING: Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond and Uppsala University Hospital.
引用
- Ladjevardi CO, Naeser Y, Dyrke U, et al. Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden. Lancet Oncol. 2025. PMID: 41167217. doi:10.1016/S1470-2045(25)00487-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。